Logo

PFSA

Profusa, Inc. Common Stock

PFSA

Profusa, Inc. Common Stock • NASDAQ
$0.17 ▲ 5.81% (+0.01)
Market Cap $7.07 M
52w High $5.50
52w Low $0.12
Dividend Yield 0%
P/E -0.24
Volume 3.47M
Outstanding Shares 41.76M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $21.709M ▲ $-22.192M ▼ 0% $-0.7 ▼ $-20.58M ▼
Q2-2025 $0 $967.084K ▼ $-8.197M ▼ 0% $-0.25 ▼ $-967.084K ▲
Q1-2025 $0 $1.424M ▲ $-2.716M ▼ 0% $-0.083 ▼ $-1.486M ▼
Q2-2024 $0 $253.13K ▼ $-397.487K ▲ 0% $-0.012 ▲ $-253.13K ▲
Q1-2024 $0 $1.314M $-2.385M 0% $-0.073 $-1.305M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.981M ▲ $4.25M ▲ $38.21M ▲ $-33.96M ▼
Q2-2025 $662.763K ▲ $1.962M ▼ $23.142M ▼ $-21.18M ▲
Q1-2025 $19K $3.239M $125.155M $-121.916M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-22.192M ▼ $-10.617M ▼ $-7.49M ▼ $20.94M ▲ $2.346M ▲ $-10.617M ▼
Q2-2025 $-6.601M ▼ $-139.173K ▲ $0 $122.475K ▼ $644.313K ▲ $-139.17K ▲
Q1-2025 $-2.716M ▼ $-537K ▼ $0 ▼ $365K ▲ $-172K ▼ $-537K ▼
Q2-2024 $1.167M ▲ $-394.878K ▲ $65.264K ▲ $330.796K ▼ $1.182K ▲ $-394.88K ▲
Q1-2024 $-2.385M $-742K $0 $610K $-132K $-742K

Five-Year Company Overview

Income Statement

Income Statement Profusa is still a pre-revenue company. Over the past several years it has reported essentially no sales and ongoing net losses. The losses appear relatively small in absolute terms, which suggests a lean cost base, but they are persistent. This pattern is typical for an early-stage medical device company that is still in development and regulatory phases rather than in full commercialization. Until product sales in Europe and later the U.S. materialize, the income statement will likely remain driven by research, clinical, and corporate spending rather than by revenue growth.

Balance Sheet

Balance Sheet The balance sheet looks very thin and highly early-stage. Recorded assets are minimal, cash balances appear close to zero in the reported years, and shareholder equity is negative. Debt has been creeping up from a low base. Negative equity and limited assets usually indicate a company that has been funded mainly by investors and lenders rather than by internally generated cash. It also means there is little balance sheet cushion if timelines slip or costs rise. Going forward, Profusa’s balance sheet strength will depend heavily on its ability to raise fresh capital, manage debt carefully, and convert its technology into commercial assets and recurring revenue.

Cash Flow

Cash Flow Cash flow from operations has been modestly negative, reflecting cash being used to fund research, clinical work, and corporate overhead, with no offsetting product revenue yet. Free cash flow is similarly negative but small in absolute terms, and there is essentially no spending on long-lived equipment so far. This pattern is consistent with a company that is still in the development phase and has not yet scaled manufacturing or commercial operations. However, cash needs are likely to increase as Profusa ramps up trials, prepares for launches, and builds sales and support capabilities. Overall, the company is dependent on outside financing to support its planned growth until products can begin to fund a meaningful portion of its operations.

Competitive Edge

Competitive Edge Profusa is trying to carve out a unique position in medical sensing by focusing on tissue-integrating biosensors that stay in the body for long periods and provide continuous, medical-grade data. Its main strengths are a deep patent portfolio around its hydrogel sensors and optical reading system, early regulatory traction in Europe for its oxygen platform, and a growing network of clinical and technology partners, including a notable collaboration on AI-based data insights. At the same time, it faces powerful competitors in areas like glucose monitoring, where large, established players already dominate. Profusa’s edge will depend on proving that its sensors are meaningfully more comfortable, longer-lasting, and clinically useful, and on navigating regulatory and reimbursement systems faster than potential imitators.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of Profusa’s story. The company has spent years developing its hydrogel-based biosensors designed to blend into body tissue and avoid the usual rejection response, which is a key scientific hurdle in long-term implantable sensing. Its first product focus is continuous oxygen monitoring for vascular and wound-care applications, with glucose monitoring and other biomarkers (like lactate and sodium) in the pipeline. This indicates a platform approach, where the same core technology can be adapted to multiple medical uses and markets. On top of the hardware, Profusa is investing in data and software, including an AI-driven portal to turn continuous chemistry readings into actionable insights for clinicians. This combination of sensor innovation and data analytics could be a strong differentiator, but it also adds technical, regulatory, and execution complexity.

Summary

Profusa is an early-stage, pre-commercial healthcare technology company with highly ambitious plans and very lean historical financials. There is essentially no revenue today, recurring operating losses, a thin balance sheet, and ongoing reliance on external funding. The investment case around the company is almost entirely about future potential rather than current financial strength: the success of its tissue-integrating biosensors, the timing and outcome of regulatory approvals, the adoption of its oxygen platform in Europe and later the U.S., and its ability to break into the crowded glucose monitoring market. If Profusa can successfully move from lab to clinic to broad commercial use, its revenue profile could change dramatically. However, there are substantial scientific, regulatory, commercial, and financing risks along the way. The story is high-innovation and high-uncertainty, with future execution far more important than the limited financial history on record today.

NEWS

November 24, 2025 · 8:15 AM UTC

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Read more

November 19, 2025 · 5:44 PM UTC

Profusa Announces Third Quarter Business and Financial Highlights

Read more

October 30, 2025 · 7:30 AM UTC

Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

Read more

October 28, 2025 · 8:30 AM UTC

Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026

Read more

October 22, 2025 · 8:30 AM UTC

Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe

Read more